Clinical Trial

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-14; most recent amendment 2025-11-25.
Status change: Recruiting → Active, Not Recruiting 2025-11-25
Trial Details
NCT Number NCT06220318
Lead Sponsor Fujian Haixi Pharmaceuticals Co., Ltd.
Conditions Solid Tumor
Enrollment 155 participants
Start Date 2023-07-19
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-28